A recent study has found that cell therapy can reduce the risk of death from COVID-19 by 60%. This is a significant finding that could potentially save many lives.
The study was conducted by researchers at the University of Maryland School of Medicine. They used a type of cell therapy called mesenchymal stem cell (MSC) therapy. MSCs are a type of cell that can be found in bone marrow and other tissues in the body. They have the ability to reduce inflammation and promote tissue repair.
The researchers recruited 24 patients with COVID-19 who were experiencing severe respiratory symptoms. They were given MSC therapy and monitored for 28 days. The results showed that 60% of the patients who received MSC therapy had a reduced risk of death compared to those who did not receive the therapy.
MSC therapy has been used in the past to treat other respiratory illnesses such as influenza and acute respiratory distress syndrome (ARDS). The therapy works by reducing inflammation in the lungs and promoting tissue repair. This is important in COVID-19 patients because the virus can cause severe inflammation in the lungs, leading to respiratory failure.
The study is still in its early stages and more research is needed to confirm the findings. However, the results are promising and suggest that MSC therapy could be an effective treatment for COVID-19.
Overall, this study provides hope for those who are suffering from COVID-19. Cell therapy could potentially save many lives and reduce the severity of the disease. As more research is conducted, we may see MSC therapy become a standard treatment for COVID-19.